Leads for drug targets can be generated in more ways than simply screening available compound collections. Further, there is never a guarantee that screening available compounds collections will lead to a satisfactory “HIT”. The Kemxtree team feels that it is critical to supplant “Hits-from-screening” strategy with alternatives.

Just as conversant with generating leads through de-convoluting “Hit-from-screening”, the Kemxtree scientific team is equally proficient at “de novo” design and generating LEADS for drug targets where a UHTS campaign does not yield satisfactory “probe molecules or HITS“. The Kemxtree team will leverage three additional strategies for generating LEADS and improving selectivity profiles “Structure-based drug discovery”, “Hypothesis-driven drug discovery” and “Fragment-based drug discovery”.

In the case where multiple “HITS” are identified for a given drug target, it is resource limiting for a given drug discovery group to follow-up on every one of them. Kemxtree believes that multiple HITS against a given drug target will afford interesting new opportunities or mitigating alternatives to discover novel drugs. We will be happy to provide our Clients’ the opportunity to harvest the 2nd , 3rd or 4th priority LEADS in a given program and find that diamond-drug in rough and progress them to the “designate clinical candidate” stage.